Candriam S.C.A. Allakos Inc. Transaction History

Candriam S.C.A.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$4.3 - $8.27 $151,080 - $290,566	-35,135 Reduced 29.92%	82,313 $366,000
Q4 2022 Feb 13, 2023	SELL	$5.66 - $8.42 $513,090 - $763,289	-90,652 Reduced 43.56%	117,448 $988,000
Q3 2022 Nov 10, 2022	BUY	$3.02 - $6.12 $628,462 - $1.27 Million	208,100 New	208,100 $1.27 Million
Q4 2021 Feb 10, 2022	SELL	$8.55 - $111.89 $796,894 - $10.4 Million	-93,204 Closed	0 $0
Q3 2021 Nov 09, 2021	BUY	$76.53 - $110.43 $1.97 Million - $2.84 Million	25,750 Added 38.17%	93,204 $9.87 Million
Q2 2021 Jul 20, 2021	SELL	$85.37 - $114.1 $127,798 - $170,807	-1,497 Reduced 2.17%	67,454 $7.21 Million
Q4 2020 Jan 22, 2021	SELL	$79.58 - $152.45 $3.42 Million - $6.54 Million	-42,921 Reduced 38.37%	68,951 $9.65 Million
Q2 2020 Jul 23, 2020	BUY	$44.04 - $80.69 $2.72 Million - $4.99 Million	61,872 Added 123.74%	111,872 $8.04 Million
Q4 2019 Jan 21, 2020	BUY	$66.49 - $137.73 $3.32 Million - $6.89 Million	50,000 New	50,000 $5,000

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $89.8M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.